The pharmaceutical manufacturer Amgen announced on Tuesday that an experimental obesity drug helped patients lose up to 20 ...
Amgen's experimental drug MariTide led to an average weight loss of up to 20% in a year-long mid-stage trial of nearly 600 ...
The pharmaceutical company's MariTide treatment performed well in a Phase 2 study but not as well as Wall Street expected.
Analysts were expecting the treatment to achieve an average weight loss of about 20% to 25% after one year of treatment, ...
Amgen (AMGN) announced positive data at 52 weeks in a double-blind, dose-ranging Phase 2 study with MariTide – maridebart ...
Amgen (NASDAQ:AMGN) today announced positive data at 52 weeks in a double-blind, dose-ranging Phase 2 study with MariTide ...
Amgen released promising results from its Phase 2 trial, but the data led to a significant decline in its stock price as Wall ...
According to phase 2 study, MariTide achieved significant weight loss in individuals with obesity or overweight, with up to ...
With Amgen’s MariTide results at the lower end of investors’ expectation of 20% to 25% weight loss, the much-anticipated ...
Upcoming data from a mid-stage study of Amgen's experimental weight-loss drug MariTide will shed light on how well it might ...
A new weight loss drug called MariTide caused 20 percent weight loss in a recent trial, even better than Wegovy or Ozempic.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback